Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N, Harigai M, Fujii T, Matsuno H, Takeuchi T, Yamamoto K, Takasaki Y, Tanigawa M, Endo Y, Hirose T, Morishima Y, Yoshii N, Mimori T, Takagi M. Kuwana M, et al. Among authors: endo y. Mod Rheumatol. 2024 Feb 26;34(2):272-286. doi: 10.1093/mr/road063. Mod Rheumatol. 2024. PMID: 37405710
Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
Sugiyama S, Sato K, Shibasaki Y, Endo Y, Uryu T, Toyoshima Y, Oya M, Miyanaga N, Saijo N, Gemma A, Akaza H. Sugiyama S, et al. Among authors: endo y. Jpn J Clin Oncol. 2020 Aug 4;50(8):940-947. doi: 10.1093/jjco/hyaa062. Jpn J Clin Oncol. 2020. PMID: 32458996 Free PMC article.
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Isogai A, Nozawa K, Nakakami A, Komaki R, Ozaki Y, Endo Y, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H. Isogai A, et al. Among authors: endo y. Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07367-x. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38797792
3,305 results